Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Chinese subjects aged 18-65, male or female；~2. Subjects with Body mass index (BMI) ≥18 (kg/m2); Male weight ≥50kg, female weight ≥45kg；~3. Subjects must meet the criteria;~4. No birth planning；~5. Understand and sign informed consent form voluntarily.~Exclusion Criteria:~1. allergic constitution；~2. Pregnant or lactating women；~3. Subjects who have been diagnosed with malignant tumors；~4. Subjects whose laboratory tests meet the conditions；~5. Subjects who have been diagnosed with severe gastrointestinal diseases；~6. Subjects who have been diagnosed with severe cardiovascular disease；~7. Subjects who have been diagnosed with severe cerebrovascular disease；~8. Subjects with history of alcohol and drug abuse；~9. Subjects who have participated in any other clinical trial；~10. Subjects who have any conditions that the investigator considers not suitable for this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- T8 tablet 0.5mg (Type: EXPERIMENTAL): Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week
- T8 tablet 1mg (Type: EXPERIMENTAL): Oral T8 tablet with HARRT, 1mg, once daily for 48 week
- Placebo (Type: PLACEBO_COMPARATOR): Oral Placebo with HARRT, once daily for 48 week

Based on this trial design, predict the completion outcome and termination type (if applicable).